AC0010(突变选择性EGFR抑制剂)治疗NSCLC首次人体I期研究
该首次人体I期研究在52例对第一代EGFR TKI获得性耐药的晚期或复发NSCLC患者中评估AC0010的安全性、药代动力学与抗肿瘤活性,未达最大耐受剂量,≥350 mg/日时客观缓解率为50.0%,推荐II期剂量为300 mg每日两次。
要点
- AC0010总体耐受性良好,3级及以上不良事件以转氨酶升高(12%)和皮疹(4%)为主。
- 每日≥350 mg时客观缓解率为50.0%,中位无进展生存期随剂量为14.0至35.6周。
- 血浆cfDNA显示T790M等位基因频率在治疗后显著下降(P<.001)。
核心结论
- AC0010在对第一代EGFR TKI获得性耐药的NSCLC患者中安全性良好并显示有前景的抗肿瘤活性,支持继续开发。
研究设计与样本
- 首次人体I期试验,采用改良三加三剂量递增设计,每日50至600 mg,28天为一周期,共报告52例患者数据。
- 通过剂量扩展纳入EGFR T790M突变患者,并在治疗前后对血浆游离DNA行二代测序。
主要发现
- 常见治疗中出现的不良事件为腹泻(75%)、皮疹(48%)和丙氨酸转氨酶升高(44%)。
- 3级及以上不良事件为转氨酶升高(12%)和皮疹(4%),最大耐受剂量未达到。
- 纳入全部评估剂量及T790M阴性患者时客观缓解率为36.5%。
- 每日350 mg及以上时客观缓解率为50.0%,Kaplan-Meier法估计的中位无进展生存期在每日350至600 mg剂量水平间为14.0至35.6周。
- 17例患者cfDNA测序显示T790M等位基因频率治疗后显著下降(自基线2.24降至部分缓解或疾病稳定时的0,P<.001)。
关键数值与推荐
- 基于药代动力学分析推荐每日两次给药,建议300 mg每日两次为推荐II期剂量。
- 耐药患者中检测到BRAF V600E突变、ROS1融合、c-Met及ERBB2扩增,但未检测到EGFR C797S突变。
临床怎么用
- 对第一代EGFR TKI耐药的NSCLC患者,AC0010每日两次300 mg可作为后续II期研究推荐剂量。
- 治疗中需重点监测腹泻、皮疹和转氨酶升高。
局限性
- 为首次人体I期研究,样本量52例,结果需更大规模研究验证。
- 耐药机制分析仅基于17例患者cfDNA测序,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: AC0010 is a mutation-selective, third-generation EGFR tyrosine kinase inhibitor (TKI). This aim of this first-in-human phase I trial was to determine the maximum tolerated dose, recommended phase II dose, schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 in patients with advanced or recurrent NSCLC and acquired resistance to a first-generation EGFR TKI. METHODS: Patients received escalating daily doses of AC0010 (50-600 mg) throughout 28-day cycles. A modified three-plus-three design was applied. Patients with EGFR T790M mutation were selected by dose expansion. Next-generation sequencing of plasma cell-free DNA was performed before and after treatment to determine mechanisms of anticancer activity and underlying acquired resistance. RESULTS: Data from 52 patients were reported. Common treatment-emergent adverse events were diarrhea (75%), skin rash (48%), and increased alanine transaminase level (44%); adverse events of grade 3 or higher were seen for increased transaminase level (12%) and skin rash (4%). The maximum tolerated dose was not reached. When all evaluated doses and patients negative for T790M were included, the overall response rate was 36.5%. At daily doses of 350 mg or higher, the overall response rate was 50.0% and the median progression-free survival estimated by the Kaplan-Meier method ranged from 14.0 to 35.6 weeks across a daily dose level from 350 mg to 600 mg. On the basis of pharmacokinetics data analysis, twice-daily administration is recommended and 300 mg twice daily is suggested as the recommended phase II dose. The cell-free DNA sequencing results from 17 patients indicate that T790M allele frequency decreased significantly after treatment with AC0010 (from 2.24 at baseline to 0 with a partial response or stable disease [p < .001]). In patients with development of resistance to AC0010, BRAF V600E mutation, ROS1 fusion, MNNG HOS Transforming gene (c-Met), and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) amplification were detected but EGFR C797S mutation was not detected. CONCLUSIONS: AC0010 had a well-tolerated safety profile and promising antitumor activity in patients with NSCLC with acquired resistance to a first-generation EGFR TKI, supporting its continued development.
引用
- Ma Y, Zheng X, Zhao H, et al. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. J Thorac Oncol. 2018. PMID: 29626621. doi:10.1016/j.jtho.2018.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。